secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2026-07-14T20:29:25+00:00
Accession:  0000105770-26-000093
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharmaceutical renews crosslicense and distribution agreements with Daikyo for 10 years
--------------------------------------------------------------------------------

- West holds 49% ownership in Daikyo; new agreements effective July 14, 2026, replace 2017 agreements as amended.
- Crosslicense covers joint development of closures, vials, cartridges, syringes, and medical device components.
- West gets exclusive license from Daikyo outside Japan (with exceptions); Daikyo gets non-exclusive license from West.
- West is exclusive distributor of Daikyo products outside Japan; Daikyo is non-exclusive distributor of West products in Japan.
- Agreements are royalty-free except for a fixed royalty on certain patents; each has a 10-year term with change-of-control termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577026000093/0000105770-26-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577026000093/wst-20260714.htm
  HTML page:      https://secwatch.observer/filing/0000105770-26-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer